Global Subcutaneous Drug Delivery Devices Market Overview:
Subcutaneous Drug Delivery Devices refer to tools that are made for the delivery of a drug or therapeutic agent via the specific route of administration. Such devices are used as a part of one or more medical treatments. These devices help in increasing the efficiency of drug delivery system by controlling dosage, time, and place of release of the drugs in the body. The rising demand for subcutaneous drug delivery is attributed to the rapid development of biologics. Moreover, the subcutaneous route of administration is generally preferred, as it enables self-medication, improves the quality of life, and thus reduces healthcare costs. The market for subcutaneous drug delivery devices is increasing due to the rising accessibility and affordability of the drug delivery devices, whereas strict regulatory requirements for approval of subcutaneous drug delivery devices may hinder the market growth.
Growth Drivers
- Rising prevalence of chronic diseases
- Increasing focus on self-administration, prevention of needlestick injuries and dosing errors
Roadblocks
- High cost of advanced delivery systems
Opportunities
- Improving economic conditions in the region
- Rising geriatric population, technological advancements, and increasing demand for improved subcutaneousdrug delivery systems
Challenges
- Strict regulatory requirements for approval of subcutaneous drug delivery devices
- Problems related to the use of drug delivery devices such as dosage error
Competitive Landscape:
The global Subcutaneous Drug Delivery Devices market including many local as well as regional players. Leading global players are focusing on strategic partnerships to improve their products and services. In addition, companies are focusing on increasing their client base to strengthen market position and to enhance product & service offerings.
Some of the key players profiled in the report are Gerresheimer AG (Germany), Medtronic Plc (United States), Ypsomed AG (Switzerland), Elcam Medical Group (Israel), Novo Nordisk (Denmark), Insulet Corporation (United States), Becton, Dickinson and Company (United States), West Pharmaceutical Services, Inc. (United States), Sanofi. (France) and PharmaJet (United States). Additionally, following companies can also be profiled that are part of our coverage like Unilife Corporation (United States) and Inolife Sciences (Canada). Analyst at AMA Research see United States Players to retain maximum share of Global Subcutaneous Drug Delivery Devices market by 2026. Considering Market by Distribution Channel, the sub-segment i.e. Hospital pharmacies will boost the Subcutaneous Drug Delivery Devices market. Considering Market by Syringe, the sub-segment i.e. Prefilled Injectable will boost the Subcutaneous Drug Delivery Devices market.
in March 2018, Sanofi S.A. announced the U.S. FDA approval for its maximum unit injection pen - Toujeo Max SoloStar. The device is designed to accommodate a volume of 900 units/mL. The device will help in reducing injection numbers and thus lower medical spending.
What Can be Explored with the Subcutaneous Drug Delivery Devices Market Study
Gain Market Understanding
Identify Growth Opportunities
Analyze and Measure the Global Subcutaneous Drug Delivery Devices Market by Identifying Investment across various Industry Verticals
Understand the Trends that will drive Future Changes in Subcutaneous Drug Delivery Devices
Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals
Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Subcutaneous Drug Delivery Devices market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Subcutaneous Drug Delivery Devices market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Subcutaneous Drug Delivery Devices Industry Investors, Subcutaneous Drug Delivery Devices Providers/Vendors, Research Professionals, Emerging Companies, Raw Material Suppliers/ Buyers, Research Institutes, Original Equipment Manufacturer, Component Supplier, Distributors, Government Body & Associations and End-user.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.